Please assess the completion status of the following clinical trial:

Trial Title: TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* completed primary TBE immunization + at least one booster immunization~* adults of both sexes between 18 and 60 years of age~* willingness to sign written informed consent form~Exclusion Criteria:~* age \< 18 and \> 60 years~* prior TBE infection~* Hepatitis A vaccination~* pregnancy and breast feeding~* acute infection on day of inclusion (day 0), body temperature \>37,9°C~* concomitant medications: systemic cortisone therapy, chemotherapy, immunosuppressive therapy 4 weeks prior to or during study~* administration of other vaccines 4 weeks before/after TBE vaccination~* planned surgery within 2 weeks before/after TBE vaccination~* Start of de-sensitization and the first 4 weeks of allergen dose escalation~* any contraindication to administration of FSME-Immun® vaccine according to manufacturer's instructions~* history of malignant disease within the last 5 years~* autoimmune diseases~* drug addictions~* plasma donors~* receipt of blood transfusions or immuno globulins within 3 month before study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Allergic patients (Type: EXPERIMENTAL): Allergic patients receive TBE booster vaccination
- Allergic patients with de-sensitization treatment (Type: EXPERIMENTAL): Allergic patients with de-sensitization treatment receive TBE booster vaccination
- Healthy controls (Type: ACTIVE_COMPARATOR): Healthy controls receive TBE booster vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).